Evaluation of Combination Tagraxofusp (SL-401) and Hypomethylating Agent (HMA) Therapy for the Treatment of Chronic Myelomonocytic Leukemia (CMML)

Conclusions: Current therapeutic options for CMML are limited and CMML remains a significant unmet medical need. Although HMA therapy has demonstrated efficacy in CMML, the effects are often limited in extent and duration. Our preclinical data, including in primary CMML samples, demonstrates a potential therapeutic role for the combination of an HMA and tagraxofusp in CMML. Further in vitro data from primary patient samples, including impact of single and dual agent therapy on immunophenoytpe and clonal architecture, as well as in vivo efficacy data, will be presented.DisclosuresChen: Stemline Therapeutics: Employment, Equity Ownership. Brooks: Stemline Therapeutics: Employment, Equity Ownership. Rampal: Constellation: Research Funding; Celgene: Honoraria; Jazz: Consultancy, Honoraria; Incyte: Honoraria, Research Funding; Stemline: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Krishnan, A., Li, B., Pagane, M., McGovern, E., Stone-Molloy, Z., Chen, J., Brooks, C., Levine, R. L., Rampal, R. K. Tags: 636. Myelodysplastic Syndromes-Basic and Translational Studies: Poster I Source Type: research